Also trades as: 0HI3.L (LSE) · $vol 0M
ARWR NASDAQ
Arrowhead Pharmaceuticals, Inc.
1W: +0.2%
1M: -9.8%
3M: -31.5%
YTD: -12.9%
1Y: +55.3%
3Y: +132.0%
5Y: -12.0%
$59.03
+0.05 (+0.08%)
Weekly Expected Move ±4.7%
$53
$55
$58
$61
$63
Credit Risk of going bust: higher than 52% of companies Debt: 9.4% of company value Bonds: $79.9M held by 47 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.78 (down 99%), Arrowhead Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $864.1M against a stock market value of $8.34B.
Distance to default 4.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $452.0M (short-term plus half of long-term), stock volatility 60.3%; Altman Z'' 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.78 (down 99%), Arrowhead Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $864.1M against a stock market value of $8.34B.
Distance to default 4.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $452.0M (short-term plus half of long-term), stock volatility 60.3%; Altman Z'' 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships3
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-06-22
Earliest Filing
2024-11-26
Latest Filing
partner: 2
investor: 1
Counterparties (Filed by ARWR)
3 relationshipsCompanies named in ARWR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Royalty Pharma Investments 2019 ICAV | RPRX | investor | Agreed to pay up to $410 million for future royalty interest in Olpasiran | 2022-11-10 | View |
| Amgen | AMGN | partner | Original licensee of Olpasiran under a 2016 collaboration and license agreement | 2022-11-10 | View |
| Horizon Therapeutics Ireland DAC | — | partner | Exclusive license agreement for ARO-XDH RNAi therapeutic | 2021-06-22 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ARWR in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-16 | Officer/Director Change; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-20 | Shareholder Vote; Exhibits | View | |
| 2026-02-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2026-01-09 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-01-06 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-11 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-02 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-15 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-19 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-02-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-07 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-12-18 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR